aTYR PHARMA INC Effective Income Tax Rate Reconciliation, Tax Contingency, Amount
aTYR PHARMA INC (ATYR) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Amount of $2.46 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxContingencies · last filed 2026-03-05
- aTYR PHARMA INC effective income tax rate reconciliation, tax contingency, amount for fiscal 2025 was $2.46M, a 59.12% decline from fiscal 2024.
- aTYR PHARMA INC effective income tax rate reconciliation, tax contingency, amount for fiscal 2024 was $6.02M, a 15.63% increase from fiscal 2023.
- aTYR PHARMA INC effective income tax rate reconciliation, tax contingency, amount for fiscal 2023 was $5.21M, a 112.27% increase from fiscal 2022.
- aTYR PHARMA INC effective income tax rate reconciliation, tax contingency, amount for fiscal 2022 was $2.45M, a 390.80% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 12 month |
|---|---|
| 2025-12-31 | $2.46M 10-K · filed 2026-03-05 |
| 2024-12-31 | $6.02M 10-K · filed 2025-03-13 |
| 2023-12-31 | $5.21M 10-K · filed 2025-03-13 |
| 2022-12-31 | $2.45M 10-K · filed 2025-03-13 |
| 2021-12-31 | $500.00K 10-K · filed 2024-03-14 |
| 2020-12-31 | $334.00K 10-K · filed 2023-03-14 |
| 2019-12-31 | $327.00K 10-K · filed 2022-03-15 |
| 2018-12-31 | $489.00K 10-K · filed 2021-03-24 |
| 2017-12-31 | $914.00K 10-K · filed 2020-03-26 |
| 2016-12-31 | $2.72M 10-K · filed 2019-03-26 |
| 2015-12-31 | $1.07M 10-K · filed 2018-03-20 |
| 2014-12-31 | $144.00K 10-K · filed 2017-03-16 |
| 2013-12-31 | $159.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |